Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed the day trading at $8.87 up 1.60% from the previous closing price of $8.73. In other words, the price has increased by $+0.14 from its previous closing price. On the day, 3406839 shares were traded. RXRX stock price reached its highest trading level at $8.94 during the session, while it also had its lowest trading level at $8.41.
Ratios:
For a better understanding of RXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 04 ’24 when Gibson Christopher sold 40,000 shares for $9.02 per share. The transaction valued at 360,800 led to the insider holds 938,524 shares of the business.
Gibson Christopher sold 25,000 shares of RXRX for $225,500 on Apr 04 ’24. The Chief Executive Officer now owns 0 shares after completing the transaction at $9.02 per share. On Apr 03 ’24, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 40,000 shares for $8.84 each. As a result, the insider received 353,600 and left with 978,524 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2.08B and an Enterprise Value of 1.74B. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.94 while its Price-to-Book (P/B) ratio in mrq is 4.48. Its current Enterprise Value per Revenue stands at 39.67 whereas that against EBITDA is -5.66.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.54. The 50-Day Moving Average of the stock is 10.97, while the 200-Day Moving Average is calculated to be 9.31.
Shares Statistics:
Over the past 3-months, RXRX traded about 7.17M shares per day on average, while over the past 10 days, RXRX traded about 4.97M shares per day. A total of 226.26M shares are outstanding, with a floating share count of 146.57M. Insiders hold about 32.08% of the company’s shares, while institutions hold 77.31% stake in the company. Shares short for RXRX as of Mar 15, 2024 were 43.52M with a Short Ratio of 6.07, compared to 38.24M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 18.55% and a Short% of Float of 27.85%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.39 and a low estimate of -$0.46, while EPS last year was -$0.34. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.38 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.49 and -$2.1 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.86, with 8 analysts recommending between -$1.12 and -$3.5.
Revenue Estimates
6 analysts predict $12.65M in revenue for the current quarter. It ranges from a high estimate of $20.8M to a low estimate of $10M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $12.13M, an estimated increase of 4.30% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $13.17M, an increase of 19.50% over than the figure of $4.30% in the same quarter last year. There is a high estimate of $20.8M for the next quarter, whereas the lowest estimate is $10.9M.
A total of 7 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83.3M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $56.16M. In the same quarter a year ago, actual revenue was $44.58M, up 26.00% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $88.43M in the next fiscal year. The high estimate is $254.9M and the low estimate is $41.89M. The average revenue growth estimate for next year is up 57.50% from the average revenue estimate for this year.
